An elderly Oklahoma woman stricken with Parkinson’s Disease lost $20,000 in a cryptocurrency ploy that was crafted as a scam ...

Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...

Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Israeli scientists have identified a promising new factor in the pathology of Parkinson’s disease that could pave the way for ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

Nir Giladi from TAU’s Faculty of Medical and Health Sciences and the Tel Aviv Sourasky Medical Center, as well as other researchers from TAU and the University of Haifa. The study was backed by the ...

THOSE afflicted with Parkinson’s disease (PD) must contend with tremors, stiffness, and uncontrollable movements in their body as a result of the deterioration of their nervous system. Proper care is ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...